Streetbeat News

Revenues

SGHT

Sight Sciences anticipates Q4 total revenue to be between $18.6M and $18.8M, surpassing the estimate of $18.18M, but marking a 9% year-over-year decrease. The company's cash position decreased slightly from $144.5M on September 30, 2023, to approximately $138M by December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:09 pm

ICCC

ImmuCell Corporation has announced preliminary sales figures for Q4, amounting to $5.1 million. The company also provided a sales forecast for the year 2023, expecting to reach $17.5 million.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:09 pm

ZUMZ

Zumiez Inc. has updated its FY23 earnings per share (EPS) and sales guidance, now expecting both to be near the lower end of its previously stated ranges. The company anticipates EPS to be close to the low end of the $0.24-$0.34 range and sales to be near the low end of the $275M-$281M range.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:08 pm

ZUMZ

Zumiez Inc. reported a 4.4% decrease in net sales and a 5.9% decrease in comparable sales for the nine-week period ending December 30. The decline in sales reflects a challenging retail environment for the company.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:07 pm

ACCD

Accolade, a healthcare technology company, has provided guidance for its fiscal year 2024 revenue, projecting it to be between $411 million and $415 million. This forecast is in line with the analyst estimate of $412.67 million.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:07 pm

URBN

Urban Outfitters reported a 10% increase in total company net sales for the two months ended December 31, 2023. The Retail segment saw an 8% increase in net sales, with comparable Retail segment net sales also rising by 6%.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:07 pm

HCAT

Health Catalyst, Inc. has announced preliminary Q4 revenue that exceeds the midpoint of their estimated range of $70.1M-$75.1M. Additionally, their FY23 revenue is also above the midpoint of the estimated range of $291.1M-$296M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:06 pm

ACCD

Accolade, Inc. has provided guidance for its Q4 revenue to be in the range of $121.5M to $125.5M, which is below the estimated $126.33M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:06 pm

ACCD

Accolade, Inc. reported an improvement in its Q3 earnings per share (EPS) from $(0.56) last year to $(0.28) this year. The company's revenue for the quarter was $99.4 million, surpassing the estimate of $96.238 million.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:05 pm

BARK

BARK, Inc. has reported preliminary total revenue for Q3 of approximately $125 million, surpassing the estimated $120.7 million.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 9:01 pm